Hologic announces launch of 2D/3D prone biopsy system at ECR

Hologic has launched its Affirm prone biopsy system in the European market. The system, which boasts both 2D and 3D capabilities for use in image-guided biopsies of the breast, was unveiled at the 2016 European Congress of Radiology.

"As screening and diagnostic technology has advanced with the widespread use of 3D mammography, it has become abundantly clear that prone biopsy technology was lagging behind," said Hologic Division President Pete Valenti said in a press release. "A significantly improved imaging capability and a streamlined workflow will provide healthcare providers with increased confidence for these critical procedures so that they can provide the best patient experience."

The company said the new system allows radiologists to target lesions more efficiently during 3D mammography screening due to its improved workflow and 360-degree coverage of the breast.

Read the full press release here.

 

John Hocter,

Digital Editor

With nearly a decade of experience in print and digital publishing, John serves as Content Marketing Manager. His professional skill set includes feature writing, content marketing and social media strategy. A graduate of The Ohio State University, John enjoys spending time with his wife and daughter, along with a number of surprisingly mischievous indoor cacti.

Around the web

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.